TY - JOUR
T1 - Correlation of Molecular Response as Measured by 18-FDG Positron Emission Tomography With Outcome After Chemoradiotherapy in Patients with Esophageal Carcinoma
AU - Konski, Andre A.
AU - Cheng, Jonathan D.
AU - Goldberg, Melvyn
AU - Li, Tianyu
AU - Maurer, Alan
AU - Yu, Jian Q.
AU - Haluszka, Oleh
AU - Scott, Walter
AU - Meropol, Neal J.
AU - Cohen, Steven J.
AU - Freedman, Gary
AU - Weiner, Louis M.
PY - 2007/10/1
Y1 - 2007/10/1
N2 - Purpose: To determine whether 18-fluorodeoxyglucose positron emission tomography (PET) computed tomography scans predict the pathologic complete response and disease-free and overall survival in patients with esophageal carcinoma undergoing definitive or preoperative chemoradiotherapy. Methods and Materials: The records of patients with esophageal carcinoma presenting for definitive or preoperative treatment and undergoing pre- and post-treatment 18-fluorodeoxyglucose PET-computed tomography scans were retrospectively reviewed. The histologic type, T stage, and nodal status were the variables investigated to determine a relationship with the baseline standardized uptake value (SUV) of the primary tumor at diagnosis. We also attempted to determine whether a relationship exists between the percent decrease in SUV and a pathologic complete response, overall and disease-free survival. Results: A total of 81 patients, 14 women and 67 men, underwent 18-fluorodeoxyglucose PET-computed tomography scanning before treatment and 63 also had post-treatment scans. T stage and tumor location predicted in univariate, but not multivariate, analysis for the initial SUV. Of the patients with a postchemoradiotherapy SUV of <2.5, 66% had tumor in the surgical specimen and 64% of patients had positive lymph nodes at surgery that were not imaged on the postchemoradiotherapy PET scan. A trend existed for post-treatment SUV and the days from radiotherapy to surgery to predict for a pathologic complete response (p = 0.09 and p = 0.08, respectively). The post-treatment SUV predicted for disease-free survival in the definitive chemoradiotherapy group (p = 0.01). Conclusions: A correlation was found between the depth of tumor invasion and the baseline SUV. The post-treatment SUV predicted for disease-free survival in the definitive chemoradiotherapy group. Caution should be exercised in using post-treatment PET scans to determine the necessity for surgical resection.
AB - Purpose: To determine whether 18-fluorodeoxyglucose positron emission tomography (PET) computed tomography scans predict the pathologic complete response and disease-free and overall survival in patients with esophageal carcinoma undergoing definitive or preoperative chemoradiotherapy. Methods and Materials: The records of patients with esophageal carcinoma presenting for definitive or preoperative treatment and undergoing pre- and post-treatment 18-fluorodeoxyglucose PET-computed tomography scans were retrospectively reviewed. The histologic type, T stage, and nodal status were the variables investigated to determine a relationship with the baseline standardized uptake value (SUV) of the primary tumor at diagnosis. We also attempted to determine whether a relationship exists between the percent decrease in SUV and a pathologic complete response, overall and disease-free survival. Results: A total of 81 patients, 14 women and 67 men, underwent 18-fluorodeoxyglucose PET-computed tomography scanning before treatment and 63 also had post-treatment scans. T stage and tumor location predicted in univariate, but not multivariate, analysis for the initial SUV. Of the patients with a postchemoradiotherapy SUV of <2.5, 66% had tumor in the surgical specimen and 64% of patients had positive lymph nodes at surgery that were not imaged on the postchemoradiotherapy PET scan. A trend existed for post-treatment SUV and the days from radiotherapy to surgery to predict for a pathologic complete response (p = 0.09 and p = 0.08, respectively). The post-treatment SUV predicted for disease-free survival in the definitive chemoradiotherapy group (p = 0.01). Conclusions: A correlation was found between the depth of tumor invasion and the baseline SUV. The post-treatment SUV predicted for disease-free survival in the definitive chemoradiotherapy group. Caution should be exercised in using post-treatment PET scans to determine the necessity for surgical resection.
KW - Adenocarcinoma/diagnostic imaging
KW - Analysis of Variance
KW - Carcinoma, Squamous Cell/diagnostic imaging
KW - Combined Modality Therapy
KW - Disease-Free Survival
KW - Esophageal Neoplasms/diagnostic imaging
KW - Esophagectomy
KW - Female
KW - Fluorodeoxyglucose F18
KW - Humans
KW - Male
KW - Neoplasm Staging
KW - Positron-Emission Tomography
KW - Radiopharmaceuticals
KW - Radiotherapy Dosage
KW - Retrospective Studies
KW - Tomography, Emission-Computed
UR - http://www.scopus.com/inward/record.url?scp=34548492286&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2007.03.053
DO - 10.1016/j.ijrobp.2007.03.053
M3 - Article
C2 - 17532577
AN - SCOPUS:34548492286
SN - 0360-3016
VL - 69
SP - 358
EP - 363
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -